ANDA 210497, held by Accord Hlthcare. Bupropion Hydrochloride.
As of Nov 16, 2026, ANDA 210497 (Bupropion Hydrochloride), held by Accord Hlthcare, was first approved by FDA on Oct 31, 2018, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 2018 | Original application | Approved | None posted |
| Bupropion Hydrochloride150MG · tablet, extended release;oral | Bupropion Hydrochloride | Rx |
| Bupropion Hydrochloride300MG · tablet, extended release;oral | Bupropion Hydrochloride | Rx |
| Nov 21, 2024 | Supplement 6Manufacturing | Approved | None posted |
| Dec 13, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 13, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 31, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters